RefleXion Expands Access to SCINTIX Therapy with First Freestanding Cancer Center
"At BHCC, we are committed to advancing cancer care by integrating the latest innovations, ensuring our patients receive the highest quality, cutting-edge treatments," said Arash (Ari) Gabayan, M.D., Chief of Radiation Oncology and Imaging at Beverly Hills Cancer Center. "We are excited to be amongst the first centers in the world to offer our patients this breakthrough technology, which uses the inherent biology of the patient's tumor to precisely direct the radiation beam to its tumor target.
"This is a totally new and exciting concept in radiation treatment delivery, and we believe that using the tumor's own biology will transform how patients are treated," Dr. Gabayan continued.
The RefleXion X1 machine with SCINTIX therapy is designed to use biology guidance to precisely treat one or more targets within the same treatment session. Early clinical cases have demonstrated that when the tumor moves, SCINTIX therapy autonomously shifts the radiation dose to follow the tumor, thereby safely delivering radiation to the tumor target while sparing radiation exposure to healthy tissue.
"We are thrilled to count BHCC and its world-class cancer physicians among our early customers and as our first freestanding cancer center," said Todd Powell, president and CEO of RefleXion. "Their commitment to providing access to cutting-edge cancer treatments like SCINTIX therapy is invaluable."
Beginning in 2025, the Centers for Medicare and Medicaid Services (CMS) will expand reimbursement for SCINTIX therapy, introducing new billing codes for FSCCs and professional reimbursement for physicians in both FSCCs and hospital outpatient departments.
"We are encouraged that CMS has expanded reimbursement for freestanding cancer centers like BHCC as this supports clinicians who advance clinical adoption of new technologies and treatments," continued Powell.
BHCC physicians consulted with Select Healthcare Solutions, a provider of turn-key medical technology solutions to independent physician groups, to integrate SCINTIX therapy into its comprehensive range of cancer treatment options.
SCINTIX therapy uses signals emitted from a patient's cancer cells to direct radiation treatment. Patients receive an injection of a small amount of a unique molecule, called a PET tracer, which the cancer cells consume. The X1 detects the signals produced in real time and uses those to determine where to deliver the radiation dose. In contrast, conventional radiotherapy uses static images of anatomy to guide treatment delivery.
About Beverly Hills Cancer Center
Beverly Hills Cancer Center provides a unique model of exceptional care, integrating advanced clinical trials, cutting-edge diagnostics, and innovative treatments. With highly skilled physicians, a dedicated staff, and a tranquil healing environment, BHCC is recognized as a leading private cancer diagnostic and treatment facility in Southern California and beyond. Learn more at www.BHCancerCenter.com.
About RefleXion Medical
RefleXion Medical develops and commercializes SCINTIX biology-guided radiotherapy, a groundbreaking treatment that uses a single radiotracer injection to transform cancer cells into real-time biological beacons to control external-beam radiotherapy delivery to single or multiple tumors. SCINTIX therapy is indicated for use in FDG-guided treatment of lung and bone tumors and is being studied for broader indications. In addition, the company offers the RefleXion® X1 system for conventional radiotherapy for all solid tumors. Learn more at https://reflexion.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250210968310/en/
Contacts
Media Contacts:
RefleXionAmy Cookacook@reflexion.com
Beverly Hills Cancer CenterSharon NemanSN@BHCancerCenter.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
an hour ago
- The Hill
Hospital at home treatment is working — Congress must now give it a future
During my (Zain's) last year of medical school, I took care of a 70-year-old woman who was admitted for a mild chronic obstructive pulmonary disease exacerbation. She was requiring slightly more oxygen than she was typically on at home and felt short of breath. She began recovering quite well during the first day of her hospital stay — stable, walking short distances and excited to go home. However, she wasn't yet ready to be discharged without any oversight. The typical next step would be to keep her in the hospital another night, continuing her exposure to the risks of inpatient medicine: hospital-acquired infection, exhaustion from the persistent monitor beeps and flashes, and another night away from the comfort of her family. However, this time was different. Instead of another inpatient night, she and her family were approached by the health system's Hospital at Home coordinator with what seemed a radical idea: the opportunity to continue her inpatient-level medical care at home, with appropriate clinical supervision. A pulse oximeter, blood pressure cuff, and tablet for virtual monitoring were delivered to her home that afternoon. A nurse visited twice daily to check vitals and administer medications, and a physician conducted a video check-in each morning. Her labs were drawn at home and her care team was on call 24/7. She was given the opportunity to heal in the comfort of her own home — and it worked. This patient's story represents the promise of hospital at home — a model of care that delivers inpatient-level treatment inside of a patient's home. A homage to home visits by physicians a century ago so richly depicted in literature and film, contemporary technology has enabled a new version of care in the comfort of patients' homes. Hospital at home has been shown to be safer for eligible patients. Eligible patients enrolled in hospital at home saw reduced mortality rates and fewer hospital-acquired infections across the board. A Mount Sinai study found hospital at home patients were nearly 50 percent less likely to experience a hospital readmission. Hospital at home also has the added benefit of reduced health care costs for the patient. But, Congress has to act — otherwise the program is at risk. The current expansion of the hospital at home model began out of necessity. In 2020, at the height of the COVID-19 pandemic, Congress and the Centers for Medicare and Medicaid Services (CMS) launched the Acute Hospital Care at Home waiver. It allowed hospitals to deliver full inpatient care to patients at home while still receiving Medicare payment under the usual Diagnosis-Related Group system — key to generating inpatient capacity when such high demands were placed on it. It also protected non-COVID-19 patients from potential infections. This emergency waiver offered hospitals a lifeline during the height of the pandemic — but it also revealed a sustainable care model with long-term potential. In December 2022 — when the initial waiver was set to expire — Congress extended it for an additional two years as part of the Consolidated Appropriations Act. It was extended again until 2024 in the American Relief Act. Now, the CMS waiver was extended until Sept. 30 as part of continuing resolutions passed earlier this year. Importantly, key legislation was introduced in the previous 118th Congress and, recently, the 119th: the Hospital Inpatient Services Modernization Act. These bipartisan bills will extend the Acute Hospital Care at Home waiver and lay the foundation for a more permanent regulatory framework. They expand eligibility, standardize oversight and give CMS the tools to collect data and evaluate long-term research outcomes. This bill should be debated, passed and signed — quickly. With the increased proportion of older Americans, our health care system continues to face added stresses at all levels. However, without legislative action, the entire program could vanish in September 2025 when the temporary waiver expires. Apart from large academic institutions with established programs, hospitals are unlikely to have the resources to invest in home-based care infrastructure without the waiver for reimbursements in place. The cost for smaller hospitals to implement telemonitoring systems and mobile nursing fleets is substantial, especially with an uncertain policy environment. This would have negative effects on especially rural communities, that already face significant health challenges and issues accessing appropriate care. A stable regulatory framework is the minimum needed to realize this model's full potential. Congress must pass the Hospital Inpatient Services Modernization Act and build a pathway toward a permanent policy solution. The data is compelling, the infrastructure is growing, and the need is real. Hospital at home is modernizing medicine, and it's time for legislation to catch up. Hospital at home has already proven it can work — what we need now is the political will to let it thrive. Zain Khawaja is an emergency medicine physician at Northwestern University. Manav Midha is a researcher at the USC Schaeffer Center for Health Policy and Economics.
Business Wire
2 hours ago
- Business Wire
CIBL, Inc. Reports Second Quarter Operating Results
RENO, Nev.--(BUSINESS WIRE)--CIBL, Inc. ('CIBL' or the 'Company'; OTC Pink ®: CIBY), a holding company with interests in broadband operations in New Hampshire, reported its financial results for the quarter ended June 30, 2025. Revenues increased 4.1% to $529,000 in the second quarter of 2025 from $508,000 in the second quarter 2024 Earnings per share were $5.60 per share in the second quarter of 2025 compared to a loss per share of $5.22 in the second quarter 2024 Cash and investments, net of zero debt, were $20,452 as of June 30, 2025 Christopher Nossokoff joined CIBL as a mergers and acquisitions advisor to provide and accelerate our interest in non-organic growth Results from Operations Three Months Ended June 30, 2025 Revenues increased 4.1% to $529,000 in the second quarter 2025 from $508,000 in the second quarter 2024 due to increased service revenues from broadband, end-user terminals and voice over internet protocol. EBITDA from operations 1 decreased 21.3% to $118,000 in the second quarter 2025 compared to $150,000 in the second quarter 2024 due to less capitalized labor for plant under construction and switch replacements. Six Months Ended June 30, 2025 Revenues increased 7.9% to $1,053,000 for the six months ended June 30, 2025 from $976,000 for the six months ended June 30, 2024 due to new services, one-time equipment revenues and system upgrades. EBITDA from operations 1 decreased 16.8% to $242,000 for the six months ended June 30, 2025 from $291,000 for the six months ended June 30, 2024 due to the increase in revenues discussed above partially offset by less capitalized labor for plant under construction and switch replacements. _______________ 1 A reconciliation of non-GAAP financial measures to the most comparable GAAP measure is provided at the end of this press release. Expand Other Highlights Capital expenditures were $45,000 and $164,000 for the six months ended June 30, 2025, and 2024, respectively. During the six months ended June 30, 2025, the Company acquired 725 of its shares at an average price of $1,690 per share. As of June 30, 2025, CIBL has 11,541 shares outstanding. Since its spin-off from LICT Corporation in 2007, CIBL has repurchased 15,325 of its shares for $21.8 million, or an average price of $1,420 per share. CIBL's Board of Directors continues to evaluate a broad range of strategic alternatives for the company to create shareholder value. About CIBL, Inc. CIBL is a holding company with interests in broadband operations. CIBL's operations consist of Bretton Woods Telephone Company and World Surfer, Inc. providers of broadband and communication services in Northern New Hampshire. CIBL is listed on OTC Pink® under the symbol CIBY and information can be obtained on our website: Cautionary Note Concerning Forward-Looking Statements To the extent this release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, it should be recognized that such information is based upon assumptions, projections and forecasts, including without limitation business conditions and financial markets, and the cautionary statements set forth in documents filed by CIBL on its website, Thus, such information is subject to uncertainties, risks and inaccuracies, which could be material, and there can be no assurance that such information will prove to be accurate. CIBL Inc. and Subsidiaries Attachment B Consolidated Balance Sheets (Unaudited) (USD in thousands, except share data) December 31, 2024 (Audited) June 30, 2024 Assets Current assets Cash and cash equivalents $ 1,594 $ 2,341 $ 1,348 Investments in United States Treasury Bills 16,550 16,598 18,841 Investment in available for sale equity securities 44 294 279 Investment in equity method limited partnership 1,706 1,645 1,595 Accounts receivable 253 284 221 Prepaid expenses 94 192 71 Materials and supplies 59 59 59 Income taxes receivable 37 - 43 Total current assets 20,337 21,413 22,457 Telecommunications, property, plant and equipment, net 907 958 771 Goodwill 337 337 337 Other intangibles, net 25 30 35 Other investments 1,708 1,636 700 Deferred income taxes 34 39 50 Other assets 59 59 71 Total assets $ 23,407 $ 24,472 $ 24,421 Liabilities Current liabilities Income taxes payable $ -- $ 14 $ -- Trade accounts payable and accrued expenses 142 138 124 Accrued liabilities 353 284 381 Total current liabilities 495 436 505 Other liabilities 46 46 59 Total liabilities 541 482 564 Equity Common stock, par value $.01, 30,000 shares authorized; 26,865, 26,865 and 26,415 issued; and 11,541, 12,266 and 12,399 outstanding -- -- -- Contributed capital 7,112 7,112 6,212 Retained earnings 37,545 37,416 37,147 Treasury stock, 15,325; 14,600; and 14,017 shares at cost (21,791 ) (20,538 ) (19,502 ) Total equity 22,866 23,990 23,857 Total liabilities and equity $ 23,407 $ 24,472 $ 24,421 Expand CIBL Inc. and Subsidiaries Attachment C EBTIDA Reconciliation (Unaudited) (USD in thousands, except share data) The following table is a reconciliation of EBITDA from operations to Net income (loss): Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net income (loss) $ 65 $ (65 ) $ 129 $ (126 ) Adjustments: Interest income (185 ) (266 ) (377 ) (521 ) Income tax expense (benefit) 20 (31 ) 34 (46 ) Depreciation and amortization 52 34 100 65 Total adjustments (113 ) (263 ) (243 ) (502 ) EBITDA (48 ) (328 ) (114 ) (628 ) Corporate office expenses 273 280 509 523 Equity in earnings of affiliated companies (107 ) 127 (133 ) 283 Unrealized and realized losses on available for sale equity securities - 71 (20 ) 113 EBITDA from operations $ 118 $ 150 $ 242 $ 291 Expand
Yahoo
4 hours ago
- Yahoo
Reejig Brings World-First Task-Level Intelligence to Galileo, Giving Leaders the Clarity to Reinvent Work for AI
Reejig's partnership with The Josh Bersin Company enables leaders to make data-driven AI transformation decisions, with visibility into exactly what work can be automated and how to redesign roles for the AI era. NEW YORK CITY, N.Y., Aug. 15, 2025 /PRNewswire/ -- Reejig, the pioneer of work intelligence and creator of the world's first Work Ontology®, has partnered with The Josh Bersin Company as the Trusted Content Partner for Galileo, the AI-powered HR expert assistant. Already trusted by global enterprises including WPP, Salesforce, Micron and IKEA, Reejig brings its detailed task-level intelligence to Galileo, giving leaders the most validated view of the work available today. Just like Google mapped the internet, Reejig has mapped work by breaking down every industry and role into its component tasks and skills. Built by world-leading workforce design experts, Reejig's Work Ontology® is powered by 23 proprietary industry ontologies, enriched with intelligence from over 130 million real jobs, and validated with billions of live work signals from the world's largest organizations - capturing the full DNA of how work is designed, executed, and evolved. This comprehensive mapping is what enables Reejig to deliver task-level intelligence - giving leaders visibility into exactly what work gets done and how it can be transformed. For Galileo, Reejig has provided its HR domain dataset, enabling leaders to see and understand the AI potential of all tasks in the HR function at a granular level of detail. Organizations looking to apply this same intelligence across finance, operations, technology, and every other function can access the full enterprise Work Ontology® directly through Reejig. The Clarity AI Transformation Has Been Missing As enterprises race to deploy AI, too many are doing so without a clear understanding of the work itself - risking wasted investment, workforce resistance, and misaligned priorities. The integration brings unprecedented task-level visibility into Galileo, enabling IT, HR, and business leaders to orchestrate AI transformation with precision — from identifying automation opportunities to re-engineering roles and reinventing work. With the Work Ontology®, leaders can: Gain complete visibility into every job, task, and process with clear, actionable data. Get the highest validated skill data by using skills based on the work being done, not inference. Plan AI transformation using work-level insights to identify automation opportunities, and work reinvention needs. Activate work intelligence to optimize resource allocation, maximize AI capabilities, and drive workforce efficiency. Siobhan Savage, CEO & Co-Founder of Reejig, said: "You can't lead an AI transformation if you can't see the work itself. Too many organizations are making AI decisions based on incomplete or outdated data, risking wasted investment and misaligned priorities. Our Work Ontology® is the critical infrastructure that makes work visible at the task level - so leaders know exactly what can be automated, what needs to evolve, and how to reinvent their workforces responsibly. By powering Galileo with this intelligence for HR, we're giving leaders the clarity, control, and confidence to redesign work for the AI era and do it at scale." Josh Bersin, CEO of The Josh Bersin Company, added: "Reejig's Work Ontology® turns Galileo into a "job task analysis" Agent instantly, helping HR and leadership teams quickly analyze job roles and find opportunities for AI transformation. We are excited to partner with Reejig, one of the leaders in AI-powered job task and work architecture tools." A New Standard for Work Intelligence Reejig's selection as the Trusted Content Partner for Galileo reinforces its position as the critical infrastructure for the AI-powered workforce. While Galileo now delivers unparalleled intelligence for HR work, the full scope of Reejig's Work Ontology® covers the entire enterprise - enabling organizations to apply the same level of precision to every function, from finance to operations to technology. By combining Reejig's granular, validated work data with Galileo's AI assistant and 25 years of Bersin research, enterprises gain the clarity, confidence, and control to: Scale AI initiatives without guesswork. Redesign roles and workflows with precision. Align talent, technology, and strategy to deliver measurable business impact. See It in Action Reejig and The Josh Bersin Company will be showcasing Galileo and Reejig live in action on September 4, 2025 in an exclusive webinar for enterprise leaders. Attendees will see how leaders can use this combined intelligence to redesign work, accelerate transformation, and unlock capacity. Register here: About Reejig Reejig is a force for workforce transformation in the AI era. Our Work Intelligence platform empowers organizations to boldly reinvent how work gets done, helping businesses thrive, individuals maximize their potential, and societies prosper. Through intelligent work orchestration, we're proving that AI isn't here to replace - it's here to empower. This is what we call Zero Wasted Potential. For more, go to About The Josh Bersin CompanyThe most trusted human capital advisors in the world. More than a million HR and business leaders rely on us to help them overcome their greatest people challenges. Thanks to our understanding of workplace issues, informed by the largest and most up-to-date data sets on workers and employees, we give leaders the confidence to make decisions in line with the latest thinking and evidence about work and the workplace. We're great listeners, too. There's no one like us, who understands this area so comprehensively and without bias. Our offerings include the industry's leading AI-powered HR expert assistant, Galileo®, fueled by 25 years of in-depth Josh Bersin Company research, case studies, benchmarks, and market information. We help CHROs and CEOs be better at delivering their business goals. We do that by helping you to manage people better. We are enablers at our core. We provide strategic advice and counsel supported by in-depth research, thought leadership, and unrivaled professional development, community, and networking opportunities. We empower our clients to run their businesses better. And we empower the market by identifying results-driven practices that make work better for every person on the planet. For more information, press only:Louisa Grundypress@ View original content to download multimedia: SOURCE Reejig
